Tricyclic fused pyrimidine compounds for use as her2 inhibitors

A compound of Formula (I):

• or a pharmaceutically acceptable salt thereof, wherein:
• X is CR5 or N;
• Y is NR6, CR7R, or O;
• Z is NR6 or O;
• Q is S, NR6, or CR7R;
• n is 1, 2, 3, or 4;
• m is 1, 2, 3, or 4;
• t is 0, 1, 2, 3, or 4;
• R1 is aryl, heteroaryl, cycloalkyl, or heterocyclyl;
• each instance of R2 is independently hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, heteroalkyl, halogen, cyano, nitro, amido, cycloalkyl, heterocyclyl, aryl, heteroaryl,
• —OR′, or
• —NR′R″, wherein R′ and R11 are independently hydrogen, alkyl, heteroalkyl, aryl, or heteroaryl, or
• R′ and R11 are taken together with nitrogen to form a cyclic moiety;
• or two R2 are taken together to form a C1-C3 alkylene;
• each instance of R3 is independently alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, heteroalkyl, halogen, hydroxyl, alkoxy, cyano, nitro, amino, amido, cycloalkyl, heterocyclyl, aryl, or heteroaryl;
• each instance of R5, R6, R7, and R1 is independently hydrogen or alkyl;
• W is
• -L-(NR6)s—C(═O)—(CR10)=CR10)—R11,
• -L-(NR6)s—C(═O)—C(═CR10R10)—R11,
• -L-(CR10=CR10)—C(═O)—(NR6)s—R11,
• -L-C(═CR10R10)—(═O)—(NR6)s—R11,
• -L-(NR6)s—S(═O)2—(CR10=CR10)—R11,
• -L-(NR6)s—S(═O)2—C(═CR10R10)—R11,
• -L-(CR10=CR10)—S(═O)2—(N6)s—R11;
• or
• -L-C(═CR10=R10)—S(═O)2—NR6)s—R11;
• L is a bond or C1-C3 alkylene;
• s is 0 or 1;
• each instance of R10 is independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, heteroalkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, or halo;
• R11 is hydrogen, —OR12, —(C1-C3 alkylene) —OR12NR12R13, —(C1-C3 alkylene) —NR12R13, cycloalkyl, —(C1-C3 alkylene)-aryl, heteroaryl, or —(C1-C3 alkylene)-heteroaryl;
• and
• R12 and R13 are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, heteroalkyl, alkoxy, cycloalkyl, heterocyclic, aryl, heteroaryl, cycloalkylalkyl, heterocyclylalkyl, arylalkyl, or heteroarylalkyl, or R12 and R13 are taken together with nitrogen to form a cyclic moiety.